Sign in or create an account to add this stock to your watchlist.
About Tocagen (NASDAQ:TOCA)
Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, and melanoma. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TOCA
CUSIPN/A
Phone858-412-8400
Debt
Debt-to-Equity Ratio0.03
Current Ratio4.56
Quick Ratio4.56
Price-To-Earnings
Trailing P/E Ratio-3.48
Forward P/E Ratio-5.93
P/E GrowthN/A
Sales & Book Value
Annual Sales$40,000.00
Price / Sales4,604.19
Cash FlowN/A
Price / CashN/A
Book Value$3.00 per share
Price / Book3.08
Profitability
EPS (Most Recent Fiscal Year)($2.66)
Net Income$-38,920,000.00
Net Margins-109,579.49%
Return on Equity-57.09%
Return on Assets-44.55%
Miscellaneous
Employees67
Outstanding Shares19,910,000
Tocagen (NASDAQ:TOCA) Frequently Asked Questions
What is Tocagen's stock symbol?
Tocagen trades on the NASDAQ under the ticker symbol "TOCA."
How were Tocagen's earnings last quarter?
Tocagen (NASDAQ:TOCA) posted its quarterly earnings data on Thursday, May, 10th. The company reported ($0.65) EPS for the quarter. The firm earned $0.01 million during the quarter. Tocagen had a negative net margin of 109,579.49% and a negative return on equity of 57.09%. View Tocagen's Earnings History.
When is Tocagen's next earnings date?
What price target have analysts set for TOCA?
2 equities research analysts have issued twelve-month target prices for Tocagen's stock. Their forecasts range from $15.00 to $24.00. On average, they anticipate Tocagen's share price to reach $19.50 in the next year. View Analyst Ratings for Tocagen.
Who are some of Tocagen's key competitors?
Some companies that are related to Tocagen include Dicerna Pharmaceuticals (DRNA), CymaBay Therapeutics (CBAY), Arcus Biosciences (RCUS), Dova Pharmaceuticals (DOVA), Aduro BioTech (ADRO), Five Prime Therapeutics (FPRX), Rigel Pharmaceuticals (RIGL), Ziopharm Oncology (ZIOP), ChemoCentryx (CCXI), Odonate Therapeutics (ODT), Lannett (LCI), BeyondSpring (BYSI), Keryx Biopharmaceuticals (KERX), Stemline Therapeutics (STML) and Prothena (PRTA).
Who are Tocagen's key executives?
Tocagen's management team includes the folowing people:
- Mr. Martin J. Duvall, CEO & Director (Age 56)
- Dr. Harry E. Gruber, Co-Founder, Pres of Science and Innovation & Director (Age 65)
- Mr. Thomas E. Darcy, Co-Founder & Director (Age 67)
- Dr. Asha Das M.D., Sr. VP & Chief Medical Officer (Age 53)
- Dr. Douglas J. Jolly Ph.D., Co-Founder and Exec. VP of Research & Pharmaceutical Devel. (Age 70)
When did Tocagen IPO?
(TOCA) raised $80 million in an IPO on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.
Has Tocagen been receiving favorable news coverage?
Media stories about TOCA stock have been trending positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Tocagen earned a coverage optimism score of 0.28 on Accern's scale. They also assigned media headlines about the company an impact score of 45.24 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Tocagen's major shareholders?
Tocagen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (2.86%), BVF Inc. IL (2.53%), Northern Trust Corp (0.91%), Russell Investments Group Ltd. (0.41%), Victory Capital Management Inc. (0.24%) and Millennium Management LLC (0.17%). Company insiders that own Tocagen stock include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Institutional Ownership Trends for Tocagen.
Which major investors are selling Tocagen stock?
TOCA stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, JPMorgan Chase & Co., Northern Trust Corp and Victory Capital Management Inc.. View Insider Buying and Selling for Tocagen.
Which major investors are buying Tocagen stock?
TOCA stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Millennium Management LLC and Rhumbline Advisers. Company insiders that have bought Tocagen stock in the last two years include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Insider Buying and Selling for Tocagen.
How do I buy shares of Tocagen?
Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tocagen's stock price today?
One share of TOCA stock can currently be purchased for approximately $9.25.
How big of a company is Tocagen?
Tocagen has a market capitalization of $182.99 million and generates $40,000.00 in revenue each year. The company earns $-38,920,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Tocagen employs 67 workers across the globe.
How can I contact Tocagen?
Tocagen's mailing address is 3030 BUNKER HILL STREET SUITE 230, SAN DIEGO CA, 92109. The company can be reached via phone at 858-412-8400 or via email at [email protected]
MarketBeat Community Rating for Tocagen (TOCA)
MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote "Outperform" if you believe TOCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TOCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Tocagen (NASDAQ:TOCA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Tocagen in the last 12 months. Their average twelve-month price target is $19.50, suggesting that the stock has a possible upside of 110.81%. The high price target for TOCA is $24.00 and the low price target for TOCA is $15.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 2.67 | 2.67 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $19.50 | $23.6667 | $23.6667 | $23.6667 |
| Price Target Upside: | 110.81% upside | 112.07% upside | 112.07% upside | 112.07% upside |
Tocagen (NASDAQ:TOCA) Consensus Price Target History
Tocagen (NASDAQ:TOCA) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Tocagen (NASDAQ:TOCA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Tocagen (NASDAQ TOCA) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 32.24%
Tocagen (NASDAQ TOCA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/19/2017 | Asha Das | SVP | Buy | 2,500 | $10.00 | $25,000.00 | 2,500 |  |
| 4/19/2017 | Harry E Gruber | Insider | Buy | 25,000 | $10.00 | $250,000.00 | | |
| 4/19/2017 | Mark G Foletta | CFO | Buy | 5,000 | $10.00 | $50,000.00 | 5,000 | |
| 4/19/2017 | Paul Schimmel | Director | Buy | 10,000 | $10.00 | $100,000.00 | 23,464 | |
(Data available from 1/1/2013 forward)
Tocagen (NASDAQ TOCA) News Headlines
| Source: |
|
Tocagen (NASDAQ:TOCA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Tocagen (NASDAQ:TOCA) Income Statement, Balance Sheet and Cash Flow Statement
Tocagen (NASDAQ TOCA) Stock Chart for Saturday, May, 26, 2018
Loading chart…
